EMEA streamlines centralised procedure
This article was originally published in Scrip
Executive Summary
The European Medicines Agencyhas published a new policy on how much time companies should have to answer questions raised by its scientific committee, theCHMP, relating to product approval submissions. The move is expected to streamline the later stages of the centralised approvals procedure and discourage what the agency describes as "premature" filings.